Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.

Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.

Item
http://www.wikidata.org/entity/Q34598903
Advancements in the treatment of pediatric acute leukemia and brain tumor - continuous efforts for 100% cureResistant mutations in CML and Ph(+)ALL - role of ponatinib.Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph(+) ALL04Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence.Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT.Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex.Overexpression of dominant-negative Ikaros 6 isoform is associated with resistance to TKIs in patients with Philadelphia chromosome positive acute lymphoblastic leukemiaIntegration of Next-Generation Sequencing to Treat Acute Lymphoblastic Leukemia with Targetable Lesions: The St. Jude Children's Research Hospital Approach.Skeletal abnormalities detected by SPECT is associated with increased relapse risk in pediatric acute lymphoblastic leukemia.T-cell-rich HLA-haploidentical hematopoietic stem cell transplantation for relapsed/refractory pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia without posttransplant tyrosine kinase inhibitor therapy.Pre-transplant achievement of negativity in minimal residual disease and French-American-British L1 morphology predict superior outcome after allogeneic transplant for Philadelphia chromosome positive acute lymphoblastic leukemia: an analysis of SouHow Surrogate and Chemical Genetics in Model Organisms Can Suggest Therapies for Human Genetic Diseases.Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic l
P2860

Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.

Item
http://www.wikidata.org/entity/Q34598903
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Impact of tyrosine kinase inhi ...... acute lymphoblastic leukemia.
@ast
Impact of tyrosine kinase inhi ...... acute lymphoblastic leukemia.
@en
Impact of tyrosine kinase inhi ...... acute lymphoblastic leukemia.
@nl
type
label
Impact of tyrosine kinase inhi ...... acute lymphoblastic leukemia.
@ast
Impact of tyrosine kinase inhi ...... acute lymphoblastic leukemia.
@en
Impact of tyrosine kinase inhi ...... acute lymphoblastic leukemia.
@nl
prefLabel
Impact of tyrosine kinase inhi ...... acute lymphoblastic leukemia.
@ast
Impact of tyrosine kinase inhi ...... acute lymphoblastic leukemia.
@en
Impact of tyrosine kinase inhi ...... acute lymphoblastic leukemia.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P932
P356
P1433
P1476
Impact of tyrosine kinase inhi ...... acute lymphoblastic leukemia.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P921
P932